HIV Medicine最新文献

{"title":"Using an automated decision support tool to improve HIV prescribing: A feasibility study","authors":"Aidan T. Ireland,&nbsp;Jennifer Ward,&nbsp;Heather Dolby,&nbsp;Christopher Lawrence","doi":"10.1111/hiv.70028","DOIUrl":"10.1111/hiv.70028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The selection of antiretroviral therapy (ART) regimens for people living with HIV is complex and dependent on individual and clinician-perceived risk factors and preferences. The British HIV Association (BHIVA) advocates cost-effective prescribing and shared decision-making between patients and clinicians. We evaluated the acceptability and potential impact of a prototype multi-patient automated decision support tool (DST) for improving individualized, safe, and cost-effective prescribing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We surveyed people living with HIV and clinicians regarding treatment preferences and the acceptability of a DST. We developed a DST to interpret electronic patient record data, using 2022 BHIVA guidelines to identify optimal ART switch options. This was applied to patients prescribed ART between June 2022 and May 2023 in the local HIV service, and potential cost savings were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among people living with HIV, 86.7% (144/166) respondents were open to switching to more cost-effective ART. While 94% (15/16) of clinician respondents prioritized lower-cost treatments where possible, only 38% (6/16) reported knowing about ART costs.</p>\u0000 \u0000 <p>Regimen switch options were identified for 274 of 503 people living with HIV meeting the inclusion criteria. Overall, potential cost savings of 28.4% of total ART spend (£26630.25 per month) were calculated if all possible switches to the most cost-effective option identified by the DST were made.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A DST based on BHIVA recommendations and using routinely collected data may be acceptable to patients, useful to clinicians, and could provide significant cost savings. A substantial proportion of people living with HIV in our cohort were open to considering changing their ART based on cost effectiveness.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"914-922"},"PeriodicalIF":2.8,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral abstracts","authors":"","doi":"10.1111/hiv.70010","DOIUrl":"https://doi.org/10.1111/hiv.70010","url":null,"abstract":"","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 S2","pages":"3-16"},"PeriodicalIF":2.8,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poster abstracts","authors":"","doi":"10.1111/hiv.70013","DOIUrl":"https://doi.org/10.1111/hiv.70013","url":null,"abstract":"","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 S2","pages":"17-137"},"PeriodicalIF":2.8,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HCV incidence in people with HIV in southwest China: A retrospective cohort study (2004–2023)","authors":"Minyang Xiao,&nbsp;Yuhua Shi,&nbsp;Yunfei Lao,&nbsp;Yanling Ma,&nbsp;Jincheng Lou,&nbsp;Zuyang Zhang,&nbsp;Liru Fu,&nbsp;Yu Han,&nbsp;Junli Huo,&nbsp;Xiaobin Zhang,&nbsp;Yan Guo,&nbsp;Manhong Jia,&nbsp;Jian Li","doi":"10.1111/hiv.70033","DOIUrl":"10.1111/hiv.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are global public health concerns. Little research has been conducted on HCV incidence in people with HIV (PWH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a retrospective cohort study to investigate HCV incidence and associated factors in PWH. HCV-negative PWH registered in national HIV databases were enrolled and followed up from 2004 to 2023. Cox proportional hazards models were utilized to identify factors associated with HCV infections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study followed 50 245 HCV-negative PWH, totaling 272 979.3 person-years (PYs) of observation. We noted an HCV incidence rate of 0.70 per 100 PYs (95% confidence interval (CI) 0.67–0.73). Multivariate analysis indicated that being female (adjusted hazard ratio [aHR] 0.70), married (aHR 0.88), and those involved in homosexual intercourse (aHR 0.57) were associated with a lower risk of HCV infection. Conversely, an increased risk was found among those aged 20–39 years (aHR 2.97), 40–59 years (aHR 3.11), ≥ 60 years (aHR 1.80), treated at county-level antiretroviral therapy (ART) clinics (aHR 1.19), township-level ART clinics (aHR 1.83), those with a history of intravenous drug use (aHR 21.72), and individuals without CD4 testing (aHR 66.05) or HIV viral load testing (aHR 2.09). A 36% relative reduction in HCV transmission (aHR 0.64) was observed from 2010 to 2015, and a 29% relative reduction (aHR 0.71) was noted after 2016 compared with the pre-2010 levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite the decrease in HCV incidence after 2010, achieving HCV elimination in PWH remains challenging. Future endeavours should prioritize improving HCV testing, intervention, and treatment in PWH.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"951-961"},"PeriodicalIF":2.8,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Perception of medical care among women living with HIV aged 40 years or older—a European-wide survey”","authors":"","doi":"10.1111/hiv.70032","DOIUrl":"10.1111/hiv.70032","url":null,"abstract":"<p>Miron VD, Sabin CA, Săndulescu O, et al. Perception working group perception of medical care among women living with HIV aged 40 years or olde—A European-wide survey. HIV. 2025;26(3):451–464. doi:10.1111/hiv.13749</p><p>The Acknowledgements section for this article was incomplete. The below statement has been added to this section:</p><p>The authors would also like to acknowledge the following collaborators in Ireland, who contributed to the distribution of the survey locally: Nijat Ahmadi (Centre of Experimental Pathogen Host Research, University College Dublin, Ireland), Laura O'Doherty (Mater Misericordiae University Hospital, University College Dublin, Ireland), Eoin Feeney (St Vincent's University Hospital, Centre of Experimental Pathogen Host Research, University College Dublin, Ireland), Stefano Savinelli (St Vincent's University Hospital, Centre of Experimental Pathogen Host Research, University College Dublin, Ireland), Helen Tuite (University Hospital Galway, Ireland), and Corinna Sadlier (Cork University Hospital, Ireland).</p><p>We apologize for this error.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70032","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal associations between social determinants of health and well-being among women living with HIV in Canada: A latent class analysis","authors":"Zerihun Admassu,&nbsp;Carmen H. Logie,&nbsp;Luissa Vahedi,&nbsp;Angela Underhill,&nbsp;Logan Kennedy,&nbsp;Kath Webster,&nbsp;Brenda Gagnier,&nbsp;Angela Kaida,&nbsp;Alexandra de Pokomandy,&nbsp;Mona R. Loutfy","doi":"10.1111/hiv.70031","DOIUrl":"10.1111/hiv.70031","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Social determinants of health (SDoH) can significantly impact overall well-being. While existing research has explored SDoH as predictors of well-being among women living with HIV, longitudinal studies examining these relationships over time remain limited. We examined SDoH typologies among women living with HIV in Canada and longitudinal associations with well-being.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using longitudinal survey data collected at three time points from women living with HIV in Canada (2013–2018), we conducted latent class analysis (LCA) to identify subgroups of SDoH indicators, including income, experiences of violence, food security, substance use, housing stability, HIV-related stigma and social support at baseline (Time-1). Multivariable linear and logistic regression examined associations between SDoH classes and well-being (depression, discrimination [gender, racial] and HIV clinical outcomes [viral load, adherence, HIV care barriers]) at Time-3.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified three distinct SDoH classes among participants (<i>n</i> = 1422, mean age = 42.8): high (<i>n</i> = 435; 30.6%), medium (<i>n</i> = 377; 26.5%) and low SDoH adversity (<i>n</i> = 610; 42.9%). In multivariate regression analyses, the high SDoH adversity class had lower odds of achieving an undetectable viral load (adjusted Odds Ratio [aOR] = 0.46; 95% CI: 0.21, 1.01; <i>p</i> = 0.050) and higher probability of facing barriers to accessing care (<i>aβ</i> = 0.32; 95% CI: 0.19, 0.45; <i>p</i> &lt; 0.001), depression (aOR = 2.52; 95% CI: 1.71, 3.71; <i>p</i> &lt; 0.001), racial discrimination (<i>aβ</i> = 3.42; 95% CI: 1.72, 5.12; <i>p</i> &lt; 0.001) and gender discrimination (<i>aβ</i> = 3.14; 95% CI: 1.42, 4.87; <i>p</i> &lt; 0.001), compared with the low SDoH adversity class at 5-year follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>SDoH adversities were associated with poor wellbeing among women living with HIV in Canada. Integrated, comprehensive person-centred care approaches that address SDoH are needed to improve health and wellbeing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"962-969"},"PeriodicalIF":2.8,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70031","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of long-acting cabotegravir plus rilpivirine in viraemic people living with HIV: A systematic review and meta-analysis.","authors":"Beatrice Barda, Giuseppe Barilaro, Paola Bellini, Giulia Turicchi, Enos Bernasconi, Marco Bongiovanni","doi":"10.1111/hiv.70025","DOIUrl":"https://doi.org/10.1111/hiv.70025","url":null,"abstract":"<p><strong>Background: </strong>Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) is currently approved as a switch strategy in people living with HIV virally suppressed on oral antiretroviral therapy. Although small reports on specific, difficult-to-treat populations demonstrated the efficacy of LA-CAB/RPV in people living with HIV and unsuppressed viraemia, cumulative data on this issue are still lacking.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis based on PRISMA guidelines using PubMed, Scopus, Google Scholar and Medline, including papers or abstracts that evaluated the use of LA-CAB/RPV in viraemic people living with HIV. Two papers were excluded as they reported only single clinical cases; one study was excluded for including only three perinatally infected subjects. Two papers were reviews and two papers and one abstract reported result from Ward 86, which were later included in a final paper. One paper presenting preliminary results from the OPERA cohort was excluded, as these data were subsequently updated. The ACTG LATITUDE (A5359) study was not included, as it did not specifically report outcomes for people living with HIV who initiated LA-CAB/RPV while viraemic. After applying these selection criteria, five papers and three abstracts were included in the meta-analysis. The main outcome was virologic success, as defined by each individual study, in people living with HIV with at least one HIV-RNA evaluation after initiating LA-CAB/RPV. We did not perform a meta-analysis on other variables due to inconsistent assessment across studies.</p><p><strong>Results: </strong>Overall, 244 people living with HIV started LA-CAB/RPV when viraemic. Most of them reported adherence, psychological or social issues that limited compliance to standard oral treatment. The cumulative probability of achieving virologic success was 87% (79%-95%). Most patients maintained adherence rates above 90% to their scheduled injection visits. Eleven patients living with HIV developed RPV-associated mutations and five CAB-associated mutations at virologic failure. No interruption of LA-CAB/RPV for adverse events was reported.</p><p><strong>Conclusions: </strong>This is the first meta-analysis that assessed the efficacy of LA-CAB/RPV in viraemic people living with HIV; oral treatment efficacy was jeopardized by low compliance due to adherence or psychological issues. Our results can justify the use of LA-CAB/RPV also in viraemic patients without alternative oral options.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mRNA vaccines against HIV: Hopes and challenges","authors":"Akmal Zubair,&nbsp;Hanbal Ahmad,&nbsp;Muhammad Muaz Arif,&nbsp;Muhammad Ali","doi":"10.1111/hiv.70024","DOIUrl":"10.1111/hiv.70024","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Since the introduction of the first licensed mRNA-based vaccines against COVID-19, there has been significant interest in leveraging this technology for other vaccines. An unprecedented surge of mRNA vaccines has emerged in preclinical, clinical, and various research phases since 2020. The rapid development of mRNA formulations, delivery methods, and manufacturing processes has made this trend foreseeable. There is an urgent demand for effective and easily transportable vaccines in regions where the virus is prevalent, and mRNA technology shows promise in addressing this need.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methodology</h3>\u0000 \u0000 <p>The data was retrieved from various databases, including Google Scholar, PubMed, Science Direct, ClinicalTrials.gov, and government websites. The following terms were used in the search strategies: HIV, vaccines, mRNA vaccines, clinical trials, and preclinical trials. A total of 35 articles were identified and subsequently screened for data regarding mRNA vaccines for HIV.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>mRNA vaccines are an effective solution for HIV treatment, as demonstrated by various research studies referenced in the article.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This review evaluates the current state of HIV-1 mRNA vaccine development, clarifies various targeting strategies, highlights recent research findings, and provides insights into the challenges and potential solutions associated with these issues. In this review, we have explored mRNA vaccines, focusing on their functional structure, design, manufacturing, and distribution methodologies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"824-838"},"PeriodicalIF":2.8,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for strengthening same-day ART initiation, tracing people living with HIV lost to follow-up and viral load monitoring mechanisms in Ethiopia","authors":"Kidanu Hurisa Chachu,&nbsp;Kefiloe Adolphina Maboe","doi":"10.1111/hiv.70022","DOIUrl":"10.1111/hiv.70022","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>To meet the intended goal of eradicating the Human Immunodeficiency Virus (HIV) epidemic by 2030, the Joint United Nations Program on HIV/Acquired Immunodeficiency Syndrome (AIDS) has set 95-95-95 targets. Ethiopia has made progress towards these targets, but challenges continue to persist.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the current same-day antiretroviral therapy (ART) initiation status and to develop strategies for strengthening same-day ART initiation, tracing HIV/AIDS patients lost to follow-up, viral suppression and retention of patients in HIV care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A three-phased (Phase 1, Phase 2 and Phase 3) exploratory sequential mixed methods design was employed in two healthcare facilities in Ethiopia. Strategies were developed based on qualitative findings from in-depth cell phone interviews with 30 healthcare providers, quantitative results from document analysis of 332 clinical records, integration of Phases 1 and 2, application of a theoretical framework, logical reasoning and review of relevant literature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Phase 1 findings highlighted key barriers to same-day ART initiation, being patient resistance due to fear, stigma and religious concerns, as well as challenges with enrolment procedures and overburdened healthcare providers. Phase 2 results indicated varying retention rates over different time intervals: 35% at 6 months (<i>n</i> = 49), 81% at 12 months (<i>n</i> = 50), 89% from 13 to 18 months (<i>n</i> = 63) and 94% at 24 months (<i>n</i> = 34), with an overall retention in HIV/Care at 59%. Additionally, viral suppression rates were observed to be 93% at 6 months, 95% at 12 months and 86% at 24 months. In Phase 3, 15 strategies were adopted after validation by healthcare experts from HIV programmes at the Federal Ministry of Health and regional health bureaus by using the modified Delphi technique.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study contributed to the understanding of same-day ART initiation in Ethiopia by identifying key challenges that are patient reluctance, socio-economic factors and adherence issues and providing actionable strategies and recommendations for improving same-day ART initiation through targeted interventions and patient-centred strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"899-913"},"PeriodicalIF":2.8,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of late HIV diagnosis and its impact on mortality: A comprehensive systematic review and meta-analysis.","authors":"Jiaqi Zhao, Mengying Gao, Di Zhao, Wenya Tian","doi":"10.1111/hiv.70023","DOIUrl":"https://doi.org/10.1111/hiv.70023","url":null,"abstract":"<p><strong>Objectives: </strong>The late diagnosis of HIV infection plays a crucial role in accelerating the disease progression and increasing the risk of death in the HIV population. However, there remains no consensus on the prevalence of late diagnosis or resulting mortality rates. Therefore, the objective of this meta-analysis was to assess both the prevalence of late diagnosis and resulting mortality rates, so as to provide valuable references and guidance for future research.</p><p><strong>Methods: </strong>PubMed, Web of Science, Embase and Cochrane database were comprehensively searched. Stata 15 was utilized to conduct a meta-analysis. Potential sources of heterogeneity were explored through subgroup analysis and meta-regression. Additionally, sensitivity analysis was performed to assess the robustness and reliability of the results.</p><p><strong>Results: </strong>This meta-analysis comprised 52 studies with 1 009 808 individuals living with HIV. The late diagnosis rate of HIV was 44.0%. The subgroup analysis showed that the late diagnosis rate was higher among individuals aged 30 years or older, men, Africans, those infected through blood transmission, those with low education, those currently unemployed and those diagnosed from 2011 to 2020. The mortality rate due to late diagnosis was 13.0%.</p><p><strong>Conclusion: </strong>The findings of this systematic review and meta-analysis indicate a relatively high prevalence of late HIV diagnosis and a high mortality rate. The issue of delayed HIV diagnosis remains pervasive and unresolved, necessitating global efforts to address it urgently. The late diagnosis rate of HIV was higher in older individuals, men, Africans, those with low education levels, those infected through blood transmission and those diagnosed in later years. Further research is imperative to identify effective strategies for promoting early detection of HIV.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143779850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}